^
Association details:
| Biomarker: | BRCA2 Y1655* + TP53 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | eprenetapopt (APR-246) (p53 reactivator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.
Published date:
05/25/2023
Excerpt:
We selected two HGSOC (PEO1-S and Kuramochi-S) and one TNBC TP53 mutant cell lines (MDA-MB-231-S)....231-S harboured a TP53 mutation (mut) (missense R280K) and BRCA wildtype (wt), in PEO1-S BRCA2 mut p.Y1655* and TP53 mut was detectable. Kuramochi-S was TP53 mut (missense D816Y) and BRCA2 mut….The combination of APR246 and carboplatin is synergistic in all 3 studied cell lines but also in the OLA resistant ones.
Secondary therapy:
carboplatin
DOI:
10.1200/JCO.2023.41.16_suppl.e17504
